Drug Profile
EMR 62204
Latest Information Update: 22 Mar 2005
Price :
$50
*
At a glance
- Originator Merck KGaA
- Class Heart failure therapies
- Mechanism of Action Sodium hydrogen antiporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 22 Mar 2005 Discontinued - Phase-II for Heart failure in Europe (PO)
- 21 May 2003 Phase-II clinical trials in Heart failure in Europe (PO)